What it's for (Indications)
- Ursodeoxycholic acid (UDCA), marketed under brand names such as Urso, is a naturally occurring bile acid primarily indicated for several hepatobiliary conditions.
- Its main clinical applications include the dissolution of radiolucent cholesterol gallstones in patients who elect not to undergo cholecystectomy or are poor surgical candidates.
- For this indication, it is effective only for stones that are primarily cholesterol-based and non-calcified, and in patients with a functioning gallbladder.
- Furthermore, UDCA is a cornerstone therapy for primary biliary cholangitis (PBC, formerly known primary biliary cirrhosis), a chronic progressive autoimmune liver disease characterized by destruction of small bile ducts within the liver.
- In PBC, UDCA aims to improve liver function, slow disease progression, and delay the need for liver transplantation.
- It is also used off-label in some specific cholestatic liver diseases, such as cystic fibrosis-associated liver disease, to improve bile flow and liver enzyme profiles.
- The therapeutic benefits of UDCA stem from its ability to alter bile acid composition and exert protective effects on hepatocytes and cholangiocytes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of ursodeoxycholic acid varies significantly depending on the indication, patient weight, and individual response, and must always be prescribed and monitored by a healthcare professional. For the dissolution of radiolucent cholesterol gallstones, the typical adult dosage is 8-10 mg/kg/day, usually administered in two or three divided doses with meals. Treatment duration can extend from several months to two years, and efficacy should be monitored periodically with ultrasonography. For primary biliary cholangitis (PBC), the recommended adult dosage is generally 13-15 mg/kg/day, also administered in two to four divided doses with food. This regimen is typically continued indefinitely to manage disease progression. Pediatric dosages, particularly for conditions like cystic fibrosis-associated liver disease, are also weight-based and tailored to the child's specific condition and response. Regular monitoring of liver function tests (e.g., alkaline phosphatase, bilirubin, transaminases) and clinical symptoms is crucial to assess treatment efficacy and adjust dosage as needed. It is vital to adhere strictly to the prescribed dosage and not to discontinue treatment without medical advice. |
Safety & Warnings
Common Side Effects
- Ursodeoxycholic acid is generally well-tolerated, but like all medications, it can cause side effects.
- The most commonly reported adverse events are gastrointestinal in nature.
- These include diarrhea, which is often dose-dependent and can sometimes be severe enough to warrant dose reduction or discontinuation.
- Other common gastrointestinal symptoms include nausea, abdominal pain, dyspepsia, and constipation.
- Less frequently, patients may experience headache, dizziness, back pain, or arthralgia.
- Allergic reactions, though rare, can occur and may manifest as rash or itching.
- In some individuals, particularly during the initial stages of treatment for PBC, there might be a transient worsening of pruritus (itching) or an increase in liver enzyme levels, which usually resolves with continued therapy or dose adjustment.
- While serious side effects are uncommon, patients should report any unusual or persistent symptoms to their healthcare provider.
- Long-term safety data supports its use in chronic conditions, but ongoing monitoring is essential.
Serious Warnings
- Black Box Warning: Ursodeoxycholic acid does not carry a formal Black Box Warning from the U.S. Food and Drug Administration (FDA). However, healthcare professionals and patients should be aware of several serious warnings that necessitate careful patient selection, monitoring, and consideration of alternative therapies in specific circumstances. These serious warnings include the potential for transient worsening of pruritus or diarrhea, particularly at the initiation of treatment for primary biliary cholangitis (PBC), which may require dose adjustment or temporary discontinuation. Patients with a complete biliary obstruction should not receive UDCA, as this could exacerbate cholestasis and lead to systemic accumulation of bile acids. Its efficacy is limited to radiolucent cholesterol gallstones; use in patients with calcified or pigment stones, or non-functioning gallbladders, is ineffective and contraindicated. Regular monitoring of liver function tests is crucial to assess response and identify any unexpected adverse hepatic events, although UDCA is generally hepatoprotective. In pregnant women, UDCA should be used only if the potential benefit justifies the potential risk to the fetus, as human data are limited. These considerations underscore the importance of careful clinical judgment and patient monitoring during UDCA therapy.
- Patients initiating ursodeoxycholic acid therapy, especially for primary biliary cholangitis, should be aware of potential transient worsening of symptoms such as pruritus during the initial weeks of treatment; this usually subsides.
- Liver function tests, including alkaline phosphatase, bilirubin, AST, and ALT, should be monitored at baseline and regularly (e.
- g.
- , every 1-3 months for the first year, then periodically) during treatment to assess therapeutic response and detect any potential hepatotoxicity, although UDCA is generally hepatoprotective.
- Caution is advised in pregnant and breastfeeding women; while animal studies have not shown significant harm, human data are limited, and the potential benefits must be weighed against risks.
- Effective contraception should be used by women of childbearing potential receiving UDCA for gallstone dissolution.
- UDCA's effectiveness for gallstone dissolution is limited to radiolucent, non-calcified cholesterol stones; calcified or pigment stones will not respond.
- Patients with gallbladder non-function or frequent episodes of biliary colic should not use UDCA for gallstone dissolution.
- Concomitant administration with certain medications, such as aluminum-based antacids, cholestyramine, colestipol, or estrogen-containing oral contraceptives, may interfere with UDCA absorption or efficacy and should be managed with appropriate dosing intervals or alternative therapies.
How it Works (Mechanism of Action)
Ursodeoxycholic acid exerts its therapeutic effects through multiple mechanisms primarily involving the alteration of bile acid composition and hepatoprotective properties. In the context of cholesterol gallstone dissolution, UDCA reduces the cholesterol saturation index of bile by decreasing the hepatic synthesis and secretion of cholesterol into bile. It also promotes the dispersion of cholesterol into liquid crystalline and micellar phases, thereby preventing cholesterol crystallization and facilitating the dissolution of existing cholesterol stones. In primary biliary cholangitis (PBC), UDCA's mechanism is more complex. It displaces more hydrophobic and potentially toxic endogenous bile acids (e.g., lithocholic acid, chenodeoxycholic acid) from the enterohepatic circulation, thereby reducing their harmful effects on cholangiocytes and hepatocytes. UDCA also has immunomodulatory properties, inhibiting the expression of pro-inflammatory cytokines and reducing cellular apoptosis. Furthermore, it stabilizes cellular membranes, enhances biliary bicarbonate secretion (leading to a 'bicarbonate umbrella' that protects cholangiocytes), and stimulates hepatobiliary secretion, improving bile flow and reducing cholestasis. These combined actions lead to improved liver function and slowed disease progression in conditions like PBC.
Commercial Brands (Alternatives)
No other brands found for this formula.